Investigation the effectiveness and non effectiveness of inhaled salbutamol in the treatment of respiratory diseases

Investigation the effectiveness of inhaled salbutamol in the treatment of transient tachypnea of the newborn

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT2017081414333N80

Enrollment

Unknown

Registered

2017-08-29

Start date

2017-09-06

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Transient tachypnoea of newborn. Transient tachypnoea of newborn

Interventions

Intervention 1: The intervention group will receive an inhaled salbutamol with dose of 0.15mg that is equal to 0.15ml per kilogram of body weight by nebulizer for 20 minutes. Intervention 2: The contr

Treatment - Drugs

Placebo

The intervention group will receive an inhaled salbutamol with dose of 0.15mg that is equal to 0.15ml per kilogram of body weight by nebulizer for 20 minutes.

The control group will receive normal saline solution 0.9% equal to 0.15 ml per kg body weight by nebulizer for 20 minutes

Eligibility

Sex/Gender

All

Age

1 Days to 2 Days

Inclusion criteria

Inclusion criteria: Inclusion criteria: Neonates with term of gestational age; Near term or after term; Having clinical symptoms and biographies in favor of TTN diagnosis; Having at least one of the radiographic TTN criteria (including hyperinflation, the presence of fluid in the transverse Fisher, etc). Exclusion criteria: Meconium aspiration history; Respiratory distress syndrome; Congenital pneumonia; Polycysthemia; Hypoglycemia; Prolonged early sepsis; Cardiovascular disease; Tachycardia greater than 180 beats per minute; Cardiac arrhythmia; Congenital anomaly

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Number of breaths. Timepoint: Before starting treatment and after treatment at intervals: 30 minutes, one and four hours after the start. Method of measurement: By physician based on the number of breaths per minute.;Percent saturation of oxygen. Timepoint: Before starting treatment and after treatment at intervals: 30 minutes, one and four hours after the start. Method of measurement: By pulse oximetry.;Heart rate. Timepoint: Before starting treatment and after treatment at intervals: 30 minutes, one and four hours after the start. Method of measurement: By pulse oximetry.	—

Measure

Time frame

Number of breaths. Timepoint: Before starting treatment and after treatment at intervals: 30 minutes, one and four hours after the start. Method of measurement: By physician based on the number of breaths per minute.;Percent saturation of oxygen. Timepoint: Before starting treatment and after treatment at intervals: 30 minutes, one and four hours after the start. Method of measurement: By pulse oximetry.;Heart rate. Timepoint: Before starting treatment and after treatment at intervals: 30 minutes, one and four hours after the start. Method of measurement: By pulse oximetry.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Shohreh Dabiri

Kermanshah University of Medical Sciences

Dr.dabiri@yahoo.com+98 83 3427 6300

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026